The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling
Open accessAbstract
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder that occurs upon mutation of either the TSC1 or TSC2 genes, which encode the protein products hamartin and tuberin, respectively. Here, we show that hamartin and tuberin function together to inhibit mammalian target of rapamycin (mTOR)-mediated signaling to eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1). First, coexpression of hamartin and tuberin repressed phosphorylation of 4E-BP1, resulting in increased association of 4E-BP1 with eIF4E; importantly, a mutant of TSC2 derived from TSC patients was defective in repressing phosphorylation of 4E-BP1. Second, the activity of S6K1 was repressed by coexpression of hamartin and tuberin, but the activity of rapamycin-resistant mutants of S6K1 were not affected, implicating mTOR in the TSC-mediated inhibitory effect on S6K1. Third, hamartin and tuberin blocked the ability of amino acids to activate S6K1 within nutrient-deprived cells, a process that is dependent on mTOR. These findings strongly implicate the tuberin-hamartin tumor suppressor complex as an inhibitor of mTOR and suggest that the formation of tumors within TSC patients may result from aberrantly high levels of mTOR-mediated signaling to downstream targets.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Loss of the TSC1–TSC2 protein complex leads to hyperactivation of mTOR complex 1 (mTORC1)18, a key signalling node that regulates cellular anabolic and catabolic processes19.”
From mTORC1 drives cell-autonomous astrocyte reactivity in tuberous sclerosis (2026) · cites this paper as [18]
In the citing paper
“The integration of the majority of external and survival signals feeding into the (m)TORC1 pathway occurs through the TSC complex (TSCC), composed of tuberous sclerosis complex protein 1 (TSC1) and TSC2, also known as hamartin and tuberin, and TBC1D7, which is the key signal integrator and negative regulator upstream of Rheb.”
From Signal integration in the (m)TORC1 growth pathway (2018) · cites this paper as Tee et al., 2002
In the citing paper
“This identification of this regulatory mechanism, shown using the human proteins, unequivocally identified TSC1-TSC2 as inhibitors of the mTORC1 signaling pathway (Inoki et al., 2002; Tee et al., 2002), specifically by virtue of TSC2 GAP activity toward the small GTPase Rheb (Castro et al., 2003; Garami et al., 2003; Inoki et al., 2003; Saucedo et al., 2003;”
From Signal integration in the (m)TORC1 growth pathway (2018) · cites this paper as Tee et al., 2002
Citations
Cites
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,914
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Self-citationRegulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545
Hara, K., Yonezawa, K., Weng, Q.-P., Kozlowski, M. T., BELHAM, C. M., & Avruch, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14484 · Cited by 1,370
Chung, J., Kuo, C. J., Crabtree, G. R., & Blenis, J. (1992) · Cell · doi:10.1016/0092-8674(92)90643-q · Cited by 1,151
Self-citationMammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093
Self-citationMalignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 971
Mammalian TOR: a homeostatic ATP sensor
Dennis, P. B., Jaeschke, A., Saitoh, M., Fowler, B., Kozma, S. C., & Thomas, G. (2001) · Science · doi:10.1126/science.1063518 · Cited by 962
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 674
Self-citationThe mRNA 5′ cap-binding protein eIF4E and control of cell growth
Sonenberg, N., & Gingras, A. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80150-6 · Cited by 673
Research works printed but not linked: 4
- E R Gomez, J R Sampson, V H Whittemore Developmental Perspectives in Psychiatry (Oxford Univ. Press, Oxford, 1999).
- T L Plank, R S Yeung, E P Henske Cancer Res 58, 4766–4770 (1998).
- Martin K. A. & Blenis J. (2002) Adv. Cancer Res. 86 in press.
- D Rousseau, A C Gingras, A Pause, N Sonenberg Oncogene 13, 2415–2420 (1996).
Cited by
Sorted by citations
Items 801–828 of 828
Induction by rapamycin and proliferation‑promoting activity of Hspb1 in a Tsc2‑deficient cell line
Kitano, T., Nishikawa, K., Takagaki, T., Sugitani, Y., Hino, O., & Kobayashi, T. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12014
Phadnis, S., & Nicolaides, T. P. (2023) · doi:10.1093/med/9780197573778.003.0017
Pereira, D. D. A., Vieira, M. W., Watanabe, C., Mariano, M. H., Marcon, N. O., Ribeiro, L. L., & Sasaki, J. N. M. (2023) · Revista Neurociências · doi:10.34024/rnc.2023.v31.15546
Esclerosis Tuberosa: patogénesis molecular y modelos animales
Piedimonte, L. R. (2006) · NeuroTarget · doi:10.47924/neurotarget2006440
Sage, E., Choudhri, A. F., Lee-Diaz, J. A., Bissler, J. J., & Wheless, J. W. (2024) · Seizure · doi:10.1016/j.seizure.2024.11.005
Lee, C. S., & Singh, A. D. (2024) · Springer eBooks · doi:10.1007/978-3-031-72433-6_4
Social and Medical Aspects of Tuberous Sclerosis Complex
Vilchis-Zapata, Z. H., & Pacheco-Pantoja, E. L. (2025) · Springer eBooks · doi:10.1007/978-3-031-40858-8_256-1
Targeting Ferroptosis in Tuberous Sclerosis Cell Line Models
Tahsin, T. (2025) · Cronfa (Swansea University) · doi:10.23889/suthesis.69835
Ocular Manifestations of Neuro-Oculo-Cutaneous Syndromes
Moodley, M., Aronow, M. E., Robles-Lopez, K., & Utz, V. M. (2025) · doi:10.1093/med/9780197659403.003.0050
Phadnis, S., & Nicolaides, T. P. (2023) · doi:10.1093/med/9780197573778.003.0017_update_001
AMP-activated protein kinase regulation of myeloid antigen presenting cell activity.
Carroll, K. (2013) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/215
Hu, J., Li, Y., Zhang, Y., Zhang, M., Li, Y., Xu, S., Wang, Y., & Yan, X. (2026) · Aquaculture Reports · doi:10.1016/j.aqrep.2026.103403
Impact des inhibiteurs de la voie mTOR sur la réponse immunitaire T anti-tumorale
Beziaud, L. (2015) · theses.fr (ABES) · doi:10.70675/02936eacz6998z4fd1zb56cz2535d854411e
Contrôle de la progression tumorale broncho-pulmonaire par FHIT : Implication du récepteur HER2
Jouida, A. (2017) · theses.fr (ABES) · doi:10.70675/d7d69aafzfaebz4f24z855dz70ea0b9a846e
de Calbiac, H. (2019) · theses.fr (ABES) · doi:10.70675/bafe951fz8332z4b0azb55bzac8a4af1955b
Control of ependymal cell differentiation by the mTOR signaling pathway
Srivastava, A. (2021) · theses.fr (ABES) · doi:10.70675/0e4dc286zfb40z4d2bza4cdzd6fdff1cc2e8
Roisné-Hamelin, G. (2024) · theses.fr (ABES) · doi:10.70675/006069a1zb2b5z45e8zbe4fz5af5e3b6e229
Tahir, I., Najar, R. A., & Rahman, A. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02922-z
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia
Pattanayak, S. P., Darawshi, O., Hajihassani, O., Winter, J. M., Weiler, N., Ott, M., Rothweiler, F., Cinatl, J. J., Michaelis, M., Lindner, D. J., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02689-4
Epilepsy and disability in adults with tuberous sclerosis complex: a 16-year retrospective analysis
Calonge, Q., Hanin, A., Dade, M., Bailly, L., Gourfinkel‐An, I., & Navarro, V. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13945-4
Li, T. L., & Bateup, H. S. (2026) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2026.102552
Molecular Pathology of Pancreatic Neuroendocrine Neoplasms
Furlan, D. (2015) · Springer eBooks · doi:10.1007/978-3-319-17235-4_20
Novel Regulation of mTOR Complex 1 Signaling by Site-Specific mTOR Phosphorylation.
Üstünel, B. E. (2012) · Deep Blue (University of Michigan)
Anabolic Effects of Amino Acids and Insulin in the Liver
Bertrand, L., & Hue, L. (2005) · Oxidative stress and disease · doi:10.1201/9781420028362.ch11
Mechanisms of Rapamycin Toxicity in Pancreatic Beta Cells
Barlow, A. D. (2011) · Figshare
Metadata
- Authors
- Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., & Blenis, J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Blenis, John
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-09-23
- Volume
- 99
- Issue
- 21
- Pages
- 13571-13576
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC129715
- OpenAlex
- W2087812126
- Cited by
- 827
- References
- 31
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 17 · 2023: 27 · 2022: 29 · 2021: 35 · 2020: 40 · 2019: 22 · 2018: 37 · 2017: 35 · 2016: 31 · 2015: 45 · 2014: 28 · 2013: 43 · 2012: 42
- FWCI
- 17.27
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-08-09)
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM 41890, GM51405, R01GM056203, GM 56203, R01GM051405, R01GM041890, R37GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- tuberous sclerosis complex, TSC1, TSC2, hamartin, tuberin, mTOR signaling, 4E-BP1, S6K1, amino acid signaling, nutrient deprivation, rapamycin resistance, protein phosphorylation, eIF4E, tumor formation
- MeSH terms
- Tuberous Sclerosis Complex 1 Protein, Tuberous Sclerosis Complex 2 Protein, Amino Acids, Carrier Proteins, Cell Line, Humans, Insulin, Models, Biological, Phosphoproteins, Phosphorylation, Protein Kinases, Proteins, Repressor Proteins, Tuberous Sclerosis, Signal Transduction, Point Mutation, Cell Cycle Proteins, Phosphatidylinositol 3-Kinases, Ribosomal Protein S6 Kinases, Tumor Suppressor Proteins, Adaptor Proteins, Signal Transducing, TOR Serine-Threonine Kinases, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
